drugset / Trial / NCT02993133

Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid.

NCT02993133

Phase 3 Completed 53 enrolled University Hospital, Limoges
NaSingle-groupOpen-labelTreatment

Summary

The main autoimmune bullous dermatoses are pemphigus and cicatricial pemphigoid. Pemphigus is an autoimmune dermatological disease characterized by the production of anti-desmoclesin antibodies 1 and 3, affecting the skin and mucous membranes.The cicatricial pemphigoid is an autoimmune dermatological disease, characterized by the production of anti-zone antibodies of the basal membrane and characterized by a predominant mucosal involvement. Mycophenolic acid (MPA) is an increasingly used form of corticosteroid. Despite its increasing use, pharmacokinetics in autoimmune bullous dermatosis remain little studied.

Timeline

Start
2016-12
Primary completion
2019-01
Completion
2019-04

Drugs

EvaluationDrugModalityDoseRoute
Subject mycophenolic acid Small molecule